@divinity24365 unki website aur reports hi padh raha hu
annual reports nahi mil rahi but
हिन्दी
Jns
1.2K posts
@altrnteacct haa farzi bag rhi hai shayad revenue hone wala hoga!
हिन्दी
@nagarajponnu74 @Yuvraj_77 under delivering since 3 quarters
so, stay cautious before looking at it for long term
English
@Yuvraj_77 Not an issue. It is an opportunity for add further quantity. If you convinced about the script need not to exit as and when.. look at long-term prospective
English
No one asked why Ujjivan SFB, Krishana Phoschem & Azad Engineering are my top 3 weekly breakout picks. ( well you should )
The answer is simple: Weekly OBV. 📈
All three are showing beautiful OBV breakouts.
For new investors:
OBV (On Balance Volume) tracks whether money is quietly flowing into or out of a stock. Think of it as the fuel gauge, while price is the speedometer.
When OBV breaks out before price, it often suggests accumulation is happening beneath the surface. Volume moves first. Price usually follows.
If you know you know…
Gnyanad Bhatt@Asset_Architect
Went through hundreds of charts this weekend and identified 9 very interesting weekly breakout candidates 🔍📊 🔹 Krishana Phoschem 🔹 Lloyds Metals & Energy 🔹 Ujjivan Small Finance Bank 🔹 Action Construction Equipment 🔹 Sri Lotus Developers 🔹 Tatva Chintan Pharma 🔹 ESAF Small Finance Bank 🔹 JG Chemicals 🔹 Azad Engineering ⭐ My Top 3 picks for the next 10-day positional trade: 🥇 Azad Engineering 🥈 Krishana Phoschem 🥉 Ujjivan Small Finance Bank Charts are lining up nicely. Let’s see how they play out this week. 🚀
English
1768 to 1613 Low Today....
Anyone buy on the dip...?
Yuvraj Singh | StocksX@Yuvraj_77
Lower Circuit on Monday. ✅ #zentech Anyone holding these stocks...?
English
@altrnteacct I can be right 75% chance
I can be wrong 25% chance.
Baki Market is supreme ✨
English
@Sundar9122024 elecon free fall mai gaya
kyu risk lena stock ab khatam hai
Indonesia
Avoid Holding Stocks on Result Day! 🚨
Buy after a good result , not before it.
Or,
If most companies in a sector are posting strong results, look for peer stocks that haven't announced their results yet.
But remember: Exit those positions before their own result date.
#DARVAS🥸
English
Jns retweetledi
📢 JSH Technical Analysis Masterclass – FREE Live Session!
I am planning to take a session this Sunday to cover the Basics of Technical Analysis 📈
Here’s what you’ll learn:
📊 How to read and interpret price charts
📉 How to spot Support & Resistance zones
📈 How to identify Market Trends
🔄 Insights into the Four Stages of the Stock Market
🎯 Stock picking
📍Comment "Interested" and I'll send you the meeting link via DM. ✅
Time: 8 PM (26th July)
⏰ Don’t miss it – it’s perfect for beginners or anyone looking to brush up on the basics!
♻️ RT / Share / Comment if you're interested!
Let’s learn and grow together 📊🔥
#TechnicalAnalysis #stockmarketsindia #TradingStrategy #stockmarkets #Wyckoff #Trading
English
ITR Form for Capital Gain
ITR-1 = LTCG upto 1.25 Lacs
ITR-2 = LTCG > 1.25 Lacs, Any CG, No Business income
ITR-3 = Capital Gain + Business Income
English
@Asset_Architect does the shareholding structure not hamper your analysis?
curious to know
English
Morepen Laboratories 61💊🧪
One of the most underrated healthcare companies in India.
Morepen is not just a pharmaceutical company.
It operates across APIs (Active Pharmaceutical Ingredients), finished formulations, diagnostic devices, home healthcare products and wellness brands, making it a diversified healthcare business rather than a pure generic pharma player.
Think of it this way:
A patient with diabetes or hypertension may use a Morepen BP monitor or glucometer at home… While the medicine they’re taking may also contain APIs manufactured by Morepen.
The company participates across multiple parts of the healthcare value chain.
Recent Business Performance (Q4 FY26):
📈 Revenue: ₹501 Cr (+15% YoY)
📈 Net Profit: ₹37 Cr (+78% YoY)
📈 Strong improvement in margins driven by higher API demand and operational efficiencies.
What’s working for them?
✅ One of India’s leading manufacturers of APIs like Loratadine, Montelukast, Atorvastatin and Desloratadine, supplying both domestic and global pharmaceutical companies.
✅ Home healthcare products (BP monitors, glucometers, thermometers and wellness devices) continue to strengthen the consumer healthcare business.
✅ Export business is expanding as global customers diversify sourcing under the China+1 strategy.
✅ Strong focus on branded formulations and consumer wellness products, improving margins and reducing dependence on commodity APIs.
Why do I like it?
Unlike many pharma companies that rely on a single business model, Morepen has built multiple growth engines.
APIs generate scale.
Branded formulations improve profitability.
Consumer healthcare creates a recognizable brand with recurring demand.
As India’s healthcare spending continues to rise, businesses operating across several parts of the value chain are likely to compound earnings over the long run.
For investors looking at the next 2–4 years, Morepen Laboratories is one of the more interesting emerging pharma stories worth tracking. 📈
Target 120 - 240
English
Sabhi log jakar so jao aaj allotment nhi aayega😂😂😂
IPO NAME:- SBI Mutual Funds
LINK TO CHECK SHARED BELOW 👇🏻
ipostatus.kfintech.com
English
@altrnteacct Post coming for it soon. Will be 11th pharma stock i am keeping track of
English
That’s what conviction looks like.
#IOLChem
Gnyanad Bhatt@Asset_Architect
IOL Chemicals & Pharmaceuticals 142 ( potential 3x-5x ) 💊🧪 Most people know it as a chemical company but they forget IOL is one of India’s leading manufacturers of Active Pharmaceutical Ingredients (APIs), with a strong presence in products like Ibuprofen, Metformin, Clopidogrel and other bulk drugs, while also manufacturing specialty chemicals used across multiple industries. Think of it this way: Every time a patient takes a common painkiller or diabetes medicine, there’s a chance the API behind it was manufactured by companies like IOL. The company isn’t selling brands… It’s supplying the essential ingredients that major pharmaceutical companies use to manufacture medicines. Recent Business Performance (Q4 FY26): 📈 Revenue: ₹663 Cr (+20% YoY) 📈 Net Profit: ₹55 Cr (+58% YoY) 📈 Margin expansion driven by better product mix and improved API realizations. What’s working for them? ✅ Pharma business is becoming the key earnings driver. ✅ Continues expanding its API portfolio beyond Ibuprofen to reduce dependence on a single molecule. ✅ Benefiting from the global China+1 sourcing shift as international customers diversify their supply chains. ✅ Ongoing investments in R&D, new APIs and capacity expansion to strengthen long-term growth. Why do I like it? Many investors still value IOL like a commodity chemical company. But the real opportunity lies in its transition towards a more diversified pharmaceutical business with higher-margin APIs. As global demand for affordable medicines keeps rising, companies with strong API manufacturing capabilities stand to benefit the most. If management continues executing well, I believe IOL can quietly become one of the more interesting pharma stories over the next few years. 📈 Target 536 - 900
English
🚗 India’s auto sales data is telling a very clear story.
Consumers are steadily moving away from petrol and diesel and shifting towards CNG & EVs.
This isn’t a temporary trend anymore. EV is here to stay.
The real opportunity now is finding the companies that will quietly benefit from this transition over the next 5–10 years.
Tag me yours in the comment and i will look its chart for you. 👇🏻👇🏻
@tsatwork @MithunSarkari @DhawalDoshi5
RushLane@rushlane
Fuel wise car retail sales in June 2026
English
@Asset_Architect I'm betting on morepen lab, you've it in our list too 🔝
English
@darvasboxtrader OPM wala tip mere liye bahot beneficial rha hai bhaiya ,thank you
Waiting for more such information
English
Sector identification can be done with help of #Volume and #RSI..
Thode din ruk jao...
Going to disrupt all stock #screening platforms for the Indian markets. 📈🚀
#DARVAS 🥸
disciplined trader@Discipline99136
@darvasboxtrader sir how to find the strong sector ??
English